Drug Development
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
FEATURED STORIES
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
ApiJect’s syringe is designed to be prefilled with a dose of a vaccine before it is shipped out to be used by doctors, pharmacists, hospitals, and many of the vaccination centers set up across the country. NBC noted that the prefilled technology had not been approved in the U.S.
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
The Swiss pharma giant quietly announced the cuts this morning in a breakdown of its first quarterly financial report.
A small study by researchers in Israel published in the journal Rheumatology identified six cases of patients developing herpes zoster rashes (shingles) after receiving the Pfizer-BioNTech vaccine.
An optimistic trend reported from the experimental drug lecanemab (BAN2401) clinical trials broaches the question of when the joint asset of Eisai Co., Ltd. and Biogen Inc. will hit the market.
This is an update on what is known about the clots and what the likely course of action is going to be.
Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.
Humanigen reported positive data from its Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL).
The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.